Bile acids for viral hepatitis

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Chen, Wendong ^a   Liu, J ^b   Gluud, C ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

Antiviral agents *therapeutic use ; Hepatitis B, chronic *drug therapy ; Hepatitis C, chronic *drug therapy ; Hepatitis, viral, human drug therapy ; Randomized controlled trials as topic

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; PLACEBO; URSODEOXYCHOLIC ACID;

ACUTE HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DELTA AGENT HEPATITIS; DIARRHEA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS E; HUMAN; INFECTION RISK; LIVER BIOPSY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 44949195877     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003181.pub2     Document Type: Review

References (111)

1. Abdelmalek 1998 {published data only} Abdelmalek MF, Harrison ME, Gross JB, Poterucha JJ, Gossard AA, Spivey JR, et al.Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid. Journal of Clinical Gastroenterology 1998;26(2):130-4. [MEDLINE: 9563925].
2. Angelico 1995a {published data only} Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Goffredo F. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial. Italian Journal of Gastroenterology 1993; Vol. 25:446.
3. *Angelico M, Gandin C, Pescarmona E, Rapicetta M, Vecchio CD, Bini A, et al.Recombinant interferon alpha and ursodeoxycholic acid versus interferon alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. The American Journal of Gastroenterology 1995;90(2):263-9. [MEDLINE: 7847298].
4. Belloni 1999 {published data only} Belloni G, Ferrari L, Balduzzi C, Barbieri F, Insolia R, Klersy C, et al.Effect of tauroursodeoxycholic acid on ALT, GGT and viral load in patients with hepatitis C virus-related chronic hepatitis with reference to the genotype. The Italian Journal of Gastroenterology and Hepatology 1999;31(5):427. [MEDLINE: 10470605].
5. Bonnand 1996 {published data only} Bonnand AM, Poupon R, Queneau PE, Trepo C, Cohard M, Vetter D, et al.Interferon alfa and ursodeoxycholic acid combination versus interferon alone in the treatment of chronic hepatitis C: Results of a randomized trial [AASLD abstract]. Hepatology 1996;24(4 Pt.2): 403A.
6. Boucher 1995 {published data only} Boucher E, Andre P, Jouanolle H, Moirand R, Guyader D, Ruffault A, et al.Treatment of chronic viral C hepatitis by interferon plus ursodeoxycholic acid: results from a controlled randomized trial in 80 patients. Hepatology 1994; Vol. 20, issue 4:169A.
7. *Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, et al.Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995;21(2):322-7. [MEDLINE: 7843700].
8. Cadranel 2003 {published data only} Cadranel JF, DiMartino V, Dorent R, Bernard B, Hoang C, Myara A, et al.Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study. Transplantation 2003;75(7):977-82. [MEDLINE: 12698083].
9. Clerici 1994 {published data only} Clerici C, Distrutti E, Gentili G, Solinas A, Miglietti M, Balo S. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis. Journal of Hepatology 1994;21(Suppl 1):S102.
10. Crosignani 1998 {published data only} Crosignani A, Budillon G, Cimino L, DelVecchio Blanco C, Loguercio C, Ideo G, et al.Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepato-Gastroenterology 1998;45(23):1624-9. [MEDLINE: 9840118].
11. Fabbri 2000 {published data only} *Fabbri C, Marchetto S, Pezzoli A, Accogli E, Fusaroli E, Azzaroli F, et al.Efficacy of ursodeoxycholic acid in association with interferon alpha for chronic hepatitis C in interferon alpha non-responder patients. European Journal of Gastroenterology & Hepatology 2000;12(5):511-5. [MEDLINE: 10833093].
12. Fabbri C, Mazzella G, Marchetto A, Pezzoli E, Accogli P, Fusaroli F, et al.Efficacy of ursodeoxycholic acid administration as adjuvant therapy together with alfa-interferon for chronic hepatitis C. Journal of Hepatology 1997; Vol. 26:S179.
13. Galský 1999 {published data only} Galský J, Bansky G, Holubova T, Konig J. Effect of ursodeoxycholic acid in acute viral hepatitis. Journal of Clinical Gastroenterology 1999;28(3):249-53. [MEDLINE: 10192613].
14. Ge 1997 {published data only} Ge Q, Huang Y. Combined interferon and ursodeoxycholic acid therapy in 48 chronic hepatitis C patients [(original title in Chinese)]. Journal of New Gastroenterology 1997;5(5):338-9.
15. Gracielle 2002 {published data only} Gracielle P, Roberta S, Ornella B, Luciana D, Alessandro R, Daniela Q, et al.A controlled randomised trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: an interferon sparing effect of t-UDCA. Hepatology Research 2002;23(4):227-36. [MEDLINE: 12191671].
16. Huang 1997 {published data only} Huang Y, Huang T, Ge Q. Ursodeoxycholic acid therapy in chronic hepatitis C patients [(original title in Chinese)]. Acta Academic Medicine CPAPF (Chinese People Armed Police Force) 1997;5(4):32-3.
17. Kawata 1994 {published data only} Kawata S, Imai Y, Tamura S, Inada M, Ito N, Inui Y, et al.Efficacy of combination therapy of interferon with ursodeoxycholic acid in chronic hepatitis C: sustained clearance of viremia after interferon discontinuation. Hepatology 1994;20(4):363A.
18. Kiso 1997 {published data only} Kiso S, Kawata S, Tamura S, Imai Y, Inui Y, Nagase T, et al.Efficacy of combination therapy of interferon alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial. Journal of Gastroenterology 1997;32(1):56-62. [MEDLINE: 9058296].
19. Leri 1994 {published data only} Leri O, De Luca D, Sinopoli MT, Parparo BS, Tubili S, Calaf HN, et al.Ursodeoxycholic acid, interferon-alfa, versus interferon-alfa + ursodeoxycholic acid in chronic C hepatitis. Mediterranean Journal of Infectious and Parasitic Diseases 1994;9:15-8.
20. Picciotto 1994 {published data only} Picciotto A, Savarino V, Bardellini E, Borzone S, Pireddu M, Sinelli N, et al.Effect of therapy with combined interferon and tauroursodeoxycholic acid in chronic hepatitis C: biochemical and virologic evaluation. Current Therapeutic Research 1994;55(6):675-81.
21. Poupon 2000 {published data only} Poupon RE, Bonnand AM, Queneau PE, Trepo C, Zarski JP, Raabe JJ. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon. Scandinavian Journal of Gastroenterology 2000;35(6):642-9. [MEDLINE: 10912666].
22. Puoti 1995 {published data only} *Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. European Journal of Gastroenterology & Hepatology 1995;7(2):151-4. [MEDLINE: 7712308].
23. Puoti C, Pannullo A, Annovazzi G, Filippi T, Magrini A. Ursodeoxycholic acid and chronic hepatitis C infection. The Lancet 1993; Vol. 341:1413-4.
24. Qing 1999 {published data only} Qing Y, Chen Y, Ma L, Liu L, Xie W, Tu X, et al.The effeicacy of ursodeoxycholic acid on chronic hepatitis [(original title in Chinese)]. Journal of North Sichuan Medical College 1999;14(1):48-50.
25. Scotto 1997 {published data only} Scotto G. The ursodeoxycholic acid for the treatment of HCV infections [L'acido ursodeossicolico per il trattamento delle infezioni da HCV]. Infezioni in Medicine 1997;3:168-73.
26. Senturk 1997 {published data only} Senturk H, Uzunalimoglu O, Batur Y, Simsek I, Mert A, Ozbay G, et al.Long-term efficacy of interferon alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis. Digestive Diseases and Sciences 1997;42(7):1438-44. [MEDLINE: 9246043].
27. Takano 1994 {published data only} Takano S, Nakamura K, Yokosuka O, Hirota K, Omata M. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;19(4):1291.
28. Tanaka 1996 {published data only} Tanaka K, Kondo M, Sakaguchi T, Saito S, Arata S, Ikeda M, et al.Efficacy of ursodeoxycholic acid in combination with interferon alpha in treating chronic hepatitis C: results of a long-term follow-up trial. Journal of Gastroenterology & Hepatology 1996;11(12):1155-60. [MEDLINE: 9034935].
29. Tsubota 1999 {published data only} Tsubota A, Kumada H, Arase Y, Chayama K, Saitoh S, Ikeda K, et al.Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. European Journal of Gastroenterology & Hepatology 1999;11(10):1077-83. [MEDLINE: 10524635].
30. Viola 1996 {published data only} Viola L, Perez V, Tanno H, Silva M, Welz G, Vilar J, et al.Predictive factors of non-response to recombinant interferon alfa 2b in patients with chronic hepatitis C (AASLD abstract). Hepatology 1996;24(4 Pt.2):594A.
31. Viola 1998 {published data only} Viola L, Fernandez JL, Tanno H, Silva M, Welz G, Ferraz M, Rendo P. A randomized controlled trial of 12-month treatment with interferon alfa 2b and ursodeoxycholic acid for chronic hepatitis C. Hepatology 1998;28(4):290A.
32. Zhou 1995 {published data only} Zhou J, Wang C, Wu S. Efficacy of ursodeoxycholic acid therapy on chronic hepatitis [(original title in Chinese)]. Journal of Clinical Hepato-Biliary Diseases 1995;11(3):148-50.
33. Zhu 1994 {published data only} Zhu Y. Efficacy of ursodeoxycholic acid therapy on chronic hepatitis C [(original title in Chinese)]. Bulletin of Nantong Medical College 1994;14(2):237-8.
34. Angelico 1995b Angelico M, Gandin C, Vecchio CD, Plat C, Bini A, Rosa TL, et al.Interferon-alpha and tauroursodeoxycholic acid in chronic hepatitis C: a novel therapeutic combination (AASLD abstract). Hepatology 1995;22(4 Pt 2):120A.
35. Attilli 1994 Attilli AF, Rusticali A, Varriale M, Carli L, Repice AM, Callea F, et al.The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. Journal of Hepatology 1994;20(3):315-20. [MEDLINE: 7912249].
36. Buzzelli 1991 Buzzelli G, Moscarella S, Focardi G, Dattolo P, Giusti A, Relli P, et al.Long-term treatment with ursodeoxycholic acid in patients with chronic active hepatitis. Current Therapeutic Research 1991;50(5):635-42.
37. Buzzelli 1992 Buzzelli G, Moscarella S, Focardi G, Dattolo P, Giusti A, Calviani L, et al.Ursodeoxycholic acid-hemisuccinate in the treatment of chronic active hepatitis. A controlled clinical study. Minerva medica 1992;83:537-40.
38. Crosignani 1991 Crosignani A, Battezzati PM, Setchell KDR, Camisasca M, Bertolini E, Roda A, et al.Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Hepatology 1991;13(2):339-44. [MEDLINE: 1671665].
39. Crosignani 1998(a) Crosignani A, Battezzati PM, Cestari C, Stabilini R, Conte D, Zappala F, et al.Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a multicentre dose-response study. Hepatology Research 1998;13:10-9.
40. Del Vecchio 1982 Del Vecchio Blanco C, Caporaso N, Gentile S, Rinaldi M, Pucci R. Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: A double-blind controlled trial. The Journal of International Medical Research 1982;10(4):278-82. [MEDLINE: 7117685].
41. Italian 1990 Italian Multicenter Group for Ursodeoxycholic Therapy in Chronic Hepatitis. UDCA improves serum liver enzymes but not liver histology in chronic hepatitis. Journal of Hepatology 1990;11(Suppl 2):S32.
42. Kadayifci 1997 Kadayifci A, Savas MC, Arsian S, Gullu IH. Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B. Journal of Clinical Gastroenterology 1997;24(2):125- 6. [MEDLINE: 9077736].
43. Lu 1995 Lu CL, Chan CY, Hwang SJ, Lu RH, Lee SD. Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 1995;10(4):432-7. [MEDLINE: 8527710].
44. Pinto 1992 Pinto A, Parini P, Novelli V, Zagari M, Sangermano A, Orsini M, et al.Effect of therapy with bis-hemisuccinate of ursodeoxycholic acid bisodic salt in patients with chronic liver diseases. Minerva Medica 1992;83(6):359-61. [MEDLINE: 1352868].
45. Podda 1989 Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Petroni ML, et al.Effect of different doses of ursodeoxycholic acid in chronic liver disease. Digestive Diseases and Sciences 1989;34(12):59-65. [MEDLINE: 2598769].
46. Podda 1990 *Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990;98(4):1044-50. [MEDLINE: 1968871].
47. Podda 1995 Podda M, Crosignani A, Battezzati PM, Buscarini L, Conte D, Notarbartolo A, et al.Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A dose-response study (AASLDabstract). Hepatology 1995;22(4 Pt 2):120A.
48. Portincasa 1993 Portincasa P, Palmieri V, Doronzo F, Vendemiale G, Altomare E, Sabba C, et al.Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis. Current Therapeutic Research 1993;53(5):521-32.
49. Rolandi 1991 Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T, et al.Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. European Journal of Clinical Pharmacology 1991;40(5):473-6. [MEDLINE: 1679391].
50. Song 1998 Song Z, Song J, Li Y. The effect of UDCA on 42 chronic hepatitis patients with persisting high level of gamma GT [(original title in Chinese)]. Chinese Journal of Intergretive Traditional and Western Medicine on Liver Diseases 1998;8(2):106-7.
51. Zhu 1997 *Zhu Y, Liang J, Lu Q. Combination of UDCA, Bing Du Zuo, and Ju Jibao for the treatment on 53 chronic hepatitis C patients (Chinese) [(original title in Chinese)]. Bulletin of Jiamusi Medical College 1997;20(1):44-5.
52. Alam 1995 Alam JJ. Interferon-beta treatment of human disease. Current Opinion in Biotechnology 1995;6(6):688-91. [MEDLINE: 8527841].
53. Armstrong 1982 Armstrong MJ, Carey MC. The hydrophobic-hydrophilic balance of bile salt. Inverse correlation between reversephase high performance liquid chromatographic mobilities andmicellar cholesterol-solubilizing capacities. Journal of Lipid Research 1982;23(1):70-80. [MEDLINE: 7057113].
54. Batta 1989 Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, et al.Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 1989;10(4):414-9. [MEDLINE: 2777202].
55. Boucher 1995 Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, et al.Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995;21(2):322-7. [MEDLINE: 7843700].
56. Brechot 1996 Brechot C. Hepatitis B and C viruses and primary liver cancer. Baillieres Clinical Gastroenterology 1996;10(2):335- 73. [MEDLINE: 8864037].
57. Brok 2005 Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews 2005 Issue 2. Art. No.: CD005445. DOI: 10.1002/14651858.CD005445. Art. No.: CD005445. DOI:10.1002/14651858.CD005445.
58. Calmus 1990 Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990;11(1):12-5. [MEDLINE: 2403961].
59. Chen 2001 Chen W, Liu JP, Gluud C. Bile acids for viral hepatitis (Protocol for a Cochrane Review). Cochrane Database of Systematic Reviews 2001, Issue 3.
60. Chen 2002 Chen W, Gluud C. Bile acids for primary sclerosing cholangitis (Protocol for a Cochrane Review). Cochrane Database of Systematic Reviews 2002, Issue 2.
61. Chen 2003 Chen W, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database of Systematic Reviews 2003 Issue 2. Art. No.: CD003626. DOI: 10.1002/14651858.CD003626.Art. No.: CD003626. DOI:10.1002/14651858.CD003626.
62. Chretien 1989 Chretien Y, Poupon R, Gherardt MF, Chazouilleres O, Labbe D, Myara A, et al.Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut 1989;30(8):1110-5. [MEDLINE: 2767508].
63. DeMets 1987 DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50. [MEDLINE: 3616287].
64. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 3802833].
65. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315(7109):629-34. [MEDLINE: 9310563].
66. Fallon 1997 Fallon HT. Chronic hepatitis C: how to recognize, when to treat. Consultant 1997;37(10):2596-604.
67. Farrell 1999 Farrell GC, Omata M, Sarin SK, Shiratori Y, Chutaputti A, Lu ZM, et al.Management of hepatitis C. Gastroenterology and Hepatology 1999;Suppl:4(i-viii).
68. Fattovich 1995 Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al.Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995;21(1):77-82. [MEDLINE: 7806171].
69. Fried 2002 Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 Suppl 1):S237-44. [MEDLINE: 12407599].
70. Fuchs 1999 Fuchs M, Stange EF. Metabolism of bile acids. In: Johannes Bircher, Jean-Pierre Benhamou, Neil McIntyre, Mario Rizzetto, Juan Rodes editor( s). Oxford Textbook of Clinical Hepatology. 2. Vol. 1, Oxford: Oxford University Press, 1999:223-56.
71. Gallo 1993 Gallo V, DeMicheli AG, Chiandussi L. Tauro-ursodeoxycholic acids vs ursodeoxycholic acid in the dissolution of biliary calculi. Result of a single blind study. La Clinica Terapeutica 1993;143(5):421-8. [MEDLINE: 8275659].
72. Gluud 2001a Gluud C. Alcoholic hepatitis: no glucocorticosteroids? . Steatohepatitis (NASH and ASH)-Falk Symposium 121. Lancaster: Kluwer Academic Publisher, 2001:322-42.
73. Gluud 2001b Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2001 Issue 4. Art. No.: CD000551. DOI: 10.1002/14651858.CD000551.Art. No.: CD000551. DOI:10.1002/14651858.CD000551.
74. Gluud 2007 Gluud C, Brok J, Gong Y, Koretz R. Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology 2007;46:734-2.
75. Goulis 1999 Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354(9184):1053-60. [MEDLINE: 10509495].
76. Guicciardi 2002 Guicciardi M, Gores GJ. Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways. Hepatology 2002;35(4):971-3. [MEDLINE: 11915048].
77. Hahn 2000 Hahn S, Williamson PR, Hutton JL, Garner P, Flynn EV. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. Statistics in Medicine 2000;19(24):3325-36. [MEDLINE: 11122498].
78. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & sons, Ltd.
79. Hoffnagle 1997 Hoffnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. The New England Journal of Medicine 1997;336(5):347-56. [MEDLINE: 9011789].
80. ICH-GCP 1997 International Conference on Harmonisation Expert Working Group. Code of Federal Regulations&International Conference on Harmonization Guidelines. Media: Parexel Barnett, 1997.
81. Jaeschke 2002 Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicological Sciences 2002;65(2):166-76. [MEDLINE: 11812920].
82. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11): 982-9. [MEDLINE: 11730399].
83. Knodell 1981 Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al.Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1(5):431-5. [MEDLINE: 7308988].
84. Larghi 1997 Larghi A, Crosignani A, Battezzati PM, Valle G, Allocca M, Invernizzi P, et al.Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Alimentary Pharmacology & Therapeutics 1997;11(2):409-14. [MEDLINE: 9146783].
85. Liaw 1999 Liaw YF, Guan R, Lau GKK, Leung N, Merican I, Stace NH, et al.Management of chronic hepatitis B. Gastroenterology and Hepatology 1999;Supplement:2 (i-viii).
86. Liu 2002 Liu J, Kjaergard LL, Gluud C. Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B. American Journal of Chinese Medicine 2002;30(1):173-6. [MEDLINE: 12067091].
87. Lok 2001 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34(6):1225-41. [MEDLINE: 11732013].
88. Maddrey 1980 Maddrey WC. Drug-related acute and chronic hepatitis. Clinical Gastroenterology 1980;9(1):213-24. [MEDLINE: 6994951].
89. Manns 2001 Manns MP, Cornberg M, Wedemeyer H. Current and future treatment of hepatitis C. Indian Journal of Gastroenterology 2001;20(Suppl 1):C47-51. [MEDLINE: 11293180].
90. Mihm 1997 Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997;25(3):735-9. [MEDLINE: 9049227].
91. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervetion efficacy reported in meta-analyses. Lancet 1998;352(9128):609-13. [MEDLINE: 9746022].
92. Myers 2001a Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al.Interferon for acute hepatitis C. Cochrane Database of Systematic Reviews 2001 Issue 4. Art. No.: CD000369. DOI: 10.1002/14651858.CD000369.Art. No.: CD000369. DOI:10.1002/14651858.CD000369.
93. Myers 2002b Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al.Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2002 Issue 2. Art. No.: CD000370. DOI: 10.1002/14651858.CD000370.Art. No.: CD000370. DOI:10.1002/14651858.CD000370.
94. Nakagawa 1990 Nakagawa M, Colombo C, Setchell KDR. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology 1990;12(2):322-34. [MEDLINE: 2391071].
95. Palmer 1972 Palmer RH. Bile acids, liver injury and liver disease. Archives of Internal Medicine 1972;130(4):606-17. [MEDLINE: 4627840].
96. Paumgartner 2002 Paumgartner G, Beuers U. Ursodeoxycholiic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36(3):525-31. [MEDLINE: 12198643].
97. Podda 1996 Podda M, Crosignani A, Battezzati PM, Quagliuolo M, Valsania C, Invernizzi P, et al.Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a dose-response study (IASL Abstract). Hepatology 1996;23(1):I-70.
98. Poynard 1997 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. Lancet 1997;349(9055):825- 32. [MEDLINE: 9121257].
99. Qiao 2002 Qiao L, Yacoub A, Studer E, Gupta S, Pei XY, Grant S, et al.Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 2002;35(4):779-89. [MEDLINE: 11915023].
100. Renault 1989 Renault PF, Hoofnagle JH. Side effects of alpha interferon. Seminar in Liver Disease 1989;9(4):273-7. [MEDLINE: 2690351].
101. Rizzetto 1986 Rizzetto M, Verme G, Gerin JL, Purcell RH. Hepatitis delta virus disease. Progress in Liver Disease 1986;8:417-31. [MEDLINE: 3520665].
102. Rodrigues 2000 Rodrigues CM, Brites D, Serejo F, Costa A, Ramalho F, De Moura MC. Apoptotic cell death does not parallel other indicators of liver damage in chronic hepatitis C patients. Journal of Viral Hepatitis 2000;7(3):175-83. [MEDLINE: 10849259].
103. Schulz 1995 Schulz KF, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. JAMA 1995;273(5):408-12. [MEDLINE: 7823387].
104. Seeff 2002 Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36(5 Suppl 1):S1-2. [MEDLINE: 12407571].
105. Sholmerich 1984 Sholmerich J, Becher MS, Schmidt KH, Schubert R, Kremer B, Felhaus S, et al.Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties. Hepatology 1984;4(4):661-7. [MEDLINE: 6745854].
106. Stapleton 1994 Stapleton JT, Lemon SM. Hepatitis A and Hepatitis E. In: HoeprichPD, JordanMC, RonaldAR editor(s). Infectious Disease. Fifth. Philadelphia: Lippincott Co, 1994:790-7.
107. Wetterslev 2007 Wetterslev J, Thorlung K, Brok J, Gluud C. Trials sequential analyses of six Cochrane Neonatal Group meta-analyses. Journal of Clinical Epidemiology 2007;(in press).
108. WHO 2000a WHO. Hepatitis B. Fact Sheet WHO/204, www.who.int/inf-fs/en/fact204.html October 2000.
109. WHO 2000b WHO. Hepatitis C. Fact Sheet WHO/164, www.who.int/inf-fs/en/fact164.html October 2000.
110. Wolfram 1999 Wolfram H, Gerlich, Thomssen R. The viruses of hepatitis. In: Bricher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J editor(s). Oxford Textbook of Clinical Hepatology. 2. Vol. 1, Oxford: Oxford University Press, 1999:827-954.
111. Zuckermann 1993 Zuckermann AR, Thomas HC. Viral Hepatitis. 1. London: Churchill Livingstone, 1993.